Study to evaluate the efficacy and safety of supreme mini s in patients with inflammatory bowel disease

Comparative Study of Suprep mini S tablet and PEG for Bowel Preparation in patients with Inflammatory Bowel Disease: prospective randomized single-blinded trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010904

Enrollment

110

Registered

2025-08-14

Start date

2025-08-14

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : We plan to compare the effectiveness of two bowel preparation agents: PEGA (polyethylene glycol with ascorbic acid

Pharmbio Pharm. Co., Ltd., Seoul, Korea) and SUPREP Mini-S tablet (Taejoon Pharm. Co., Ltd., Seoul, Korea). Both agents are approved for use in patients requiring bowel preparation and are considered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Patients aged 18 years or older with inflammatory bowel disease (IBD) who are scheduled to undergo colonoscopy ? Patients who have signed the informed consent form

Exclusion criteria

Exclusion criteria: ? Patients with severe obstructive intestinal strictures ? Patients with severe acute ulcerative colitis ? Patients with conditions that may cause gastric stasis (e.g., diabetic gastroparesis) ? Patients with severe constipation (defined as fewer than three bowel movements per week, or requiring regular or intermittent laxatives) ? Patients in whom full colonoscopy is not possible (e.g., those who have undergone colectomy) ? Patients with significant dehydration ? Patients with a history of cirrhosis, ascites, or severe inflammatory conditions ? Patients with congestive heart failure or cardiovascular disease (including ischemic heart disease or coronary artery disease within the past 6 months) ? Patients with severe renal impairment (serum creatinine > 3 mg/dL for more than 6 months, or estimated GFR < 30 mL/min/1.73 m²) ? Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency ? Patients with cognitive or intellectual disabilities ? Patients who refuse to sign the informed consent form ? Patients classified as ASA (American Society of Anesthesiologists) Class III or higher ? Patients without laboratory results (within the past 3 months) for: Na, K, Cl, Mg, Calcium, Phosphate, BUN/Creatinine, and estimated GFR (eGFR by MDRD or CCr %) ? Pregnant women

Design outcomes

Primary

Measure	Time frame
Quality of bowel cleansing	—

Secondary

Measure	Time frame
Safety	—

Countries

Korea, Republic of

Contacts

Public ContactJongbeom Shin

Inha University Hospital

shinjongv@naver.com+82-2-2612-7983

Outcome results